Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy

Possick, Jennifer D.

doi:10.1016/j.ccm.2016.12.012

Cited by 36 publications

(29 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This IRAE has been found to be more common with anti-PD-1 than anti-CTLA-4 therapy. 120 Reported rates of pneumonitis in UC trials with anti-PD-1 agents were 1.1%–4.1%, with 0.2%–2.3% of patients experiencing grade ≥3 pulmonary toxicity. 23 , 53 However, there are concerns that rates of pneumonitis in clinical practice may be higher than observed in trials, and a multicenter post-marketing analysis involving various tumors revealed pneumonitis rates >5% with anti-PD-1 monotherapy, though grade ≥3 events remained infrequent at <1%.…”

Section: Introductionmentioning

confidence: 98%

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook

Gopalakrishnan¹,

Koshkin²,

Ornstein³

et al. 2018

TCRM

View full text Add to dashboard Cite

Bladder cancer is the sixth most common cancer in the US and most tumors have urothelial (transitional cell) histology. Platinum-based chemotherapy has long been the standard of care in advanced disease, but long-term outcomes have largely remained poor. Since the peak incidence of bladder cancer is in the eighth decade of life and beyond, medical comorbidities may often limit the use of chemotherapy. Immune checkpoint inhibitors with their favorable toxicity profiles and notable antitumor activity have ushered in a new era in the treatment of advanced urothelial cancer (UC) with five agents targeting the PD-1/PD-L1 pathway being recently approved by the US Food and Drug administration. A plethora of clinical trials are ongoing in diverse disease settings, employing agents targeting PD-1/PD-L1 and related immune checkpoint pathways. While reactivating anti-tumor immunity, these agents may lead to a unique constellation of immune-related adverse events, which may warrant discontinuation of therapy and potential use of immunosuppression. Novel combinations with various treatment modalities and optimal sequencing of active therapies are being investigated in prospective clinical trials and retrospective registries. At the era of precision molecular medicine, and since patients do not respond uniformly to these agents, there is a growing need for identification and validation of biomarkers that can accurately predict treatment response and assist in patient selection. This review discusses current updates and future directions of immunotherapy in advanced UC.

show abstract

Section: Introductionmentioning

confidence: 98%

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook

Gopalakrishnan¹,

Koshkin²,

Ornstein³

et al. 2018

TCRM

View full text Add to dashboard Cite

show abstract

“…Tapasztalataink alapján a kezelést a betegeink jól tolerálják, de immunmediálta nemkívánatos eseményekkel itt is kell számolnunk, amelyek azonban jóval ritkábban és enyhébb formában fordulnak el, mint az ipilimumabnál. Leggyakrabban ezek a reakciók a pajzsmirigyet és a tüdőt érinthetik, azonban okozhatnak bőrtüneteket is (13,14). A fenti immunonkológiai készítményeket egymással kombinálva (ipilimu-mab+nivolumab) néhány betegnél adtuk.…”

Section: Immunterápiaunclassified

New diagnostic methods and treatment options in dermatooncology

Baltás¹,

Kis²,

Korom³

et al. 2019

BVSZ

View full text Add to dashboard Cite

ÖSSZEFOGLALÁSA szerzők összefoglalják a 25 éve Dobozy Attila akadémikus úr kezdeményezésére megalakult onkodermatológiai munkacsoport által kezelt kórképek új diagnosztikai és kezelési lehetőségeit. Az általános diagnosztikai és kezelési elvek mellett bemutatják a módszerek és a készítmények jellemzőit, röviden jellemzik terápiás hatékonyságukat és saját tapasztalataikat. Kulcsszavak: konfokális mikroszkópia -célzott kezelés -immunterápia -elektrokemoterápia SUMMARYThe authors provide an overview of the novel diagnostic and treatment methods used in the dermatooncology unit, which was initiated 25 years ago by Attila Dobozy academician. Besides the general principles of the diagnostic and therapeutic interventions, they present shortly their efficacy and their own experiences.

show abstract

“…However, imaging findings are nonspecific and distinguishing ICI-pneumonitis from radiation-induced pneumonitis and pulmonary infections can be challenging. The cessation of ICI therapy alone is sufficient in mild pneumonitis cases and corticosteroids are typically used for treatment of more severe, symptomatic cases [8,9]. Most irAEs respond to corticosteroids and resolve within 3 months [10].…”

Section: Introductionmentioning

confidence: 99%

Pulmonary Complications Secondary to Immune Checkpoint Inhibitors

Albitar

Duma

Leventakos

et al. 2020

International Journal of Chronic Diseases

View full text Add to dashboard Cite

Background. Immune checkpoint inhibitors (ICI) have changed the landscape in the treatment of a number of cancers. Immune-related adverse events (irAEs) have emerged as a serious clinical problem with the use of ICI. Methods. All oncology patients diagnosed with pulmonary complications secondary to ICI at Mayo Clinic Rochester from January 1, 2012 to December 31, 2018 were reviewed. Demographics, comorbidities, smoking, and oncologic history were analyzed. Results. A total of 10 patients developed pulmonary complications secondary to ICI. Seven patients were men (70%), and the median age at diagnosis was 61.5 (IQR 55.8-69.3) years. All patients had stage IV disease. Melanoma was the most common malignancy. Seven (70%) patients had a positive smoking history, and 6 (60%) were obese (BMI>30). Most cases were grade 2 pneumonitis (70%). One patient with grade 4 pneumonitis required endotracheal intubation and a prolonged course of systemic corticosteroids (>30 days). Eight (80%) patients received prior radiation therapy. The median time from initiation of ICI to pneumonitis diagnosis was 3.5 months. Conclusion. Melanoma was the most common malignancy, the majority of patients had grade 2 pneumonitis and required treatment with steroids, and all patients affected by ICI-related pneumonitis had stage IV malignancy. Potential risk factors included smoking history, prior radiotherapy, obesity, and advance stage at the time of ICI initiation. Extrapulmonary irAEs are common in patients with pneumonitis.

show abstract

Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy

Cited by 36 publications

References 45 publications

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook

New diagnostic methods and treatment options in dermatooncology

Pulmonary Complications Secondary to Immune Checkpoint Inhibitors

Contact Info

Product

Resources

About